BriaCell Therapeutics Corp. (BCTX), a clinical-stage biotechnology company, on Wednesday announced that the independent Data Safety Monitoring Board (DSMB) has issued its fourth consecutive positive recommendation following review of safety data from Phase 3 study of Bria-IMT plus immune checkpoint inhibitor in patients with metastatic breast cancer.
The DSMB raised no safety concerns and recommended that the study continue without modifications.
BriaCell's ongoing pivotal Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration (FDA).
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.